29 November 2016 – Evolva (SIX: EVE) Evolva announces the appointment of Oliver Walker as its Chief Financial Officer (CFO) effective 1st December 2016.
Oliver Walker is a finance executive with more than 20 years of experience in international companies, both listed and privately-held, and was active in high growth industries and mature industries alike. Amongst other senior positions he was previously CFO of several leading Life Sciences companies, including Sivantos (Singapore), Nobel Biocare, Sonova and Stratec (all Switzerland). His experience covers all aspects of finance including M&A, capital market transactions, treasury, reporting and fundraising. Oliver has an MSc in Business Administration & Economics at the University of Berne. He is a Swiss national, born in 1969.
Neil Goldsmith, CEO of Evolva said, “I look forward to working with Oliver to take Evolva to the next stage. His experience as an entrepreneurial CFO in diverse life science, high tech and manufacturing companies will be very useful to Evolva. Oliver has a strong track record in driving operations and managing growth and brings an extensive network, both in the Swiss financial sector and abroad.”
Oliver said, “I am excited to join Evolva and make a contribution to bringing this dynamic and innovative company to strong and sustainable profitability. Jakob has given the company a solid financial foundation and I am confident my experience will be valuable in building on this basis.”
The current CFO, Jakob Dynnes Hansen, will remain at Evolva on a part-time basis to secure a smooth transition and is expected to depart in the second quarter of 2017. Jakob will return to his native Denmark, taking up a part time CFO position at Acesion Pharma, a young pharma-biotech company.
– ends –